Targeting toll-like receptor 4 with cli-095 (tak-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer

HIGHLIGHTS

• who: S. Fan from the the Research Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (IRB ID number, )Details of the , metastatic lymph node samples with IIA-IIIB NSCLC and lymph node metastasis were provided in our previous study [13]. Patients with lymphadenitis or primary malignancies of the lymph node were excluded. Palliative care or surgical biopsy following informed consent was administered to , patients with inoperable Stage IIIbIV primary NSCLC. have published the article: Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.